Skip to main content
. 2023 Nov 23;12(12):2036. doi: 10.3390/antiox12122036

Figure 3.

Figure 3

Kidney morphology and function were improved with AKT-1005 treatment in CD1 mice injected with Ad.sFlt-1. (a,b) H&E analysis of kidney tissue from AKT-1005-treated mice shows ameliorated glomerular endotheliosis (b) compared to vehicle-treated control mice (a) on gd17. Endotheliosis presents as endothelial swelling in the glomeruli of maternal kidneys from sFlt1-overexpressing mice. (c) Average glomerular endotheliosis severity scored based on blinded analysis. Mann–Whitney-U test, median (IQR): ****: p < 0.0001. n = 6 animals from each group. (d–g) Electron microscopy analysis of kidney tissue from AKT-1005-treated mice (e,g) shows ameliorated glomerular endotheliosis compared to vehicle-treated mice (d,f) (scale bars: (a,b): 100 μm; (d): 4 μm; (e): 2 μm; (f): 6 μm; and (g): 8 μm). (h) Cystatin C ELISA from urine samples indicates improved kidney function in AKT-1005-treated mice (n = 9) compared to vehicle control (n = 8). Mann–Whitney-U test, median (IQR): *: p < 0.05.